Kedudukan dalam Saham
#29654
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Harga Saham
$0.68377137
Disegerakkan terakhir: 2023-05-23
Perubahan (1 hari)
-0.60%
Perubahan (1 tahun)
0.00%
Perdagangan Medivir AB (publ) (MVIR-B)
Harga MVIR-B dengan permodalan pasaran b
Modal pasaran bagi Medivir AB (publ)(MVIR-B)
Modal Pasaran: $20.23M
Sehingga August 2026, Medivir AB (publ) mempunyai modal pasaran sebanyak $20.23M. Ini menjadikan Medivir AB (publ) syarikat ke-29654th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Medivir AB (publ) dari 2000 hingga 2026
MVIR-B berbanding dengan 5 teratas yang paling popular stocks
| Harga MVIR-B |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.307T
|
+26,236,559.14%
|
|
|
|
|
$4.551T
|
+22,499,511.59%
|
|
|
|
|
$4.154T
|
+20,539,797.21%
|
|
|
|
|
$3.589T
|
+17,742,300.50%
|
|
|
|
|
$2.797T
|
+13,827,998.65%
|
